|
04/06/2016
|
Summary ToggleTokai Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference
|
|
03/30/2016
|
Summary ToggleTokai Announces Dosing of First Patient in Phase 2 Expansion Study of Galeterone in Enzalutamide-Refractory mCRPC Patients
|
|
03/21/2016
|
Summary ToggleTokai Strengthens Development Team Through the Addition of Kelly Lindert, M.D., as Executive Vice President and Head of Development
|
|
03/10/2016
|
Summary ToggleTokai Pharmaceuticals Reports Full Year 2015 Financial Results
|
|
03/10/2016
|
Summary ToggleOticPharma to Present at the 28th Annual ROTH Conference
|
|
02/22/2016
|
Summary ToggleOticPharma to Present at the 2016 BIO CEO & Investor Conference
|
|
01/08/2016
|
Summary ToggleTokai Announces Presentation of New Data Highlighting Unique Galeterone Mechanism at ASCO Genitourinary Cancers Symposium
|
|
01/07/2016
|
Summary ToggleTokai Announces Update on ARMOR3-SV and Expanded Galeterone Clinical Development Program
|
